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Abstract
Background: Current knowledge suggests that small intestinal overgrowth participates in the pathogenesis of
irritable bowel syndrome. It is questionable if this association is modulated by intake of proton pump inhibitors (PPIs).
Methods: In a prospective study, quantitative cultures of duodenal aspirates were performed for aerobic species in 897
consecutive patients undergoing upper GI tract endoscopy. SIBO was defined as equal to or more than 103 cfu/ml. The
effect of PPI intake on the relationship between SIBO and IBS was the primary endpoint.
Results: Analysis among patients without any history of PPI intake (n = 713) showed that odds ratio (OR) for IBS in the
event of SIBO was 5.63 (3.73–8.51, p < 0.0001); this was 4.16 (1.91–9.06) when analysis was done among patients with
history of PPI intake (n = 184, p: 0.498 between patients without and with PPI intake). Multiple logistic regression
analysis found that factors independently associated with SIBO were age above or equal to 60 years (OR: 2.36),
body mass index more than or equal to 22 kg/m2 (OR: 0.60), presence of IBS (OR: 6.29), type 2 diabetes mellitus
(OR: 1.59) and gastritis (OR: 0.47).
Conclusions: The association between IBS and SIBO was completely independent from PPI intake. Although gastritis
was protective against SIBO, results show that PPI intake cannot prime SIBO.
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Background
Several studies published the last few years support an
association between small intestinal bacterial overgrowth
(SIBO) and irritable bowel syndrome (IBS) [1–4]. SIBO
represents the overgrowth of bacterial species that
usually predominate in the large bowel in the proximal
small intestine. As a result of SIBO, fermentation of
dietary carbohydrates by these bacteria leads to over-
production of gas and to the generation of symptoms
of IBS. Most of existing studies linking SIBO and IBS
use for the diagnosis of SIBO lactulose or glucose
breath tests [1–4]. However the gold standard of
diagnosis is the culture of the content of the proximal
part of the small intestine. In a recent survey of our
group, 320 consecutive patients undergoing upper GI
tract endoscopy were studied. Fluid was collected
from the third part of the duodenum and quantitatively
cultured. Using a cut-off of 103 cfu/ml of colonic type
bacteria, the frequency of SIBO was 19.4 %. SIBO
was significantly linked with odds ratio 5.64 with the
presence of IBS (p < 0.0001) [5].
To dates, a number of papers suggest that the linkage
between SIBO and IBS could be an epiphenomenon of
the chronic intake of proton pump inhibitors (PPIs)
leading to changes of the intestinal pH and promoting
the colonization by large intestinal flora [6, 7]. In a re-
cent meta-analysis, an association was found between
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intake of PPIs and development of SIBO only for studies
comparing incidence of SIBO before and post-treatment
with PPIs within the same population but not when
comparing with an independent control population [8].
Available studies do not comment on the type of PPI
intake, the dose regimen and the existence of an asso-
ciation between IBS and PPI intake [6–8]. As a conse-
quence, great heterogeneity is generated if indeed an
association between SIBO and PPI intake exists. Our co-
hort of 320 patients using forward step-wise logistic re-
gression analysis showed that the linkage between SIBO
and IBS was independent from the intake of PPIs [5]. Over
the years, this prospective cohort has been expanded to
904 patients. We aim, using this cohort of 904 patients in-
cluding the previously published 320 patients, to provide a
definitive answer on the association between SIBO and
PPI based on the gold standard for SIBO and to determine
the association between IBS and PPIs as well.
Methods
Study design
This prospective study took place during the period
September 2009 to March 2013. Patients who were
subject to upper GI tract endoscopy in the Department of
Gastroenterology of Sismanogleion General Hospital of
Athens were eligible for the study. Every patient was
allowed to be enrolled once after written informed con-
sent. The study protocol was approved by the Ethics Com-
mittee of the Sismanogleion General Hospital of Athens.
Inclusion criteria were: a) age ≥ 18 years; b) written in-
formed consent; and c) clinical indication for upper GI
tract endoscopy. Exclusion criteria were: a) infection by
the human immunodeficiency virus; b) chronic infection
by the hepatitis B and hepatitis C viruses; c) Child Pugh
liver cirrhosis stages 2 and 3; d) active GI tract bleeding;
e) gastroesophageal reflux disease (GERD); f ) systemic
sclerosis; g) any antibiotic intake the last one month
prior to endoscopy; and h) inflammatory bowel disease.
Fluid from the third portion of the duodenum was
collected during upper GI tract endoscopy. In case of pa-
tients with little fluid in the duodenum, the endoscope was
approached close to the intestinal wall to allow the aspir-
ation of the biggest possible amount of fluid. Never water
was flushed in the duodenal lumen before completion of
fluid aspiration. The samples were immediately transported
and quantitatively cultured using serial dilutions in sterile
NaCl 0.9 % under aerobic conditions. An aliquot of 0.1 ml
was plated onto MacConckey agar (Becton Dickinson,
Conckeysville Md) and incubated for 18 h at 350C. Bacter-
ial growth was determined after multiplying the number of
isolated bacteria with the respective dilution factor. Identi-
fication of bacteria was done as described previously [5].
The following information was recorded for each patient:
age, gender, height, weight, reason for endoscopy, endo-
scopic findings, other diseases and intake of any medica-
tion. Specifically, full information regarding the type and
the duration of PPI intake was registered. A patient was
considered to have history of PPI intake if he/she had been
administered one PPI for at least the last one month on a
daily basis by his/her case-history. Adherence to PPI treat-
ment was based on case-history and daily dose and start
and stop dates were confirmed by the information pro-
vided in the prescription system for every single patient.
Based on their history, patients were classified as suffer-
ing from IBS if they met the following criteria: recurrent
Fig. 1 Study flow chart. Abbreviations: GI; gastrointestinal; SIBO: syndrome of intestinal bacterial overgrowth
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abdominal pain or discomfort at least 3 days per month in
the previous 3 months associated with 2 or more of the
following [9]: i) Improvement with defecation; ii) onset as-
sociated with a change in frequency of stool; and iii) onset
associated with a change in form (appearance) of stool.
Patients with IBS were further sub-classified based on
their symptoms into three bowel habit subtypes ie
diarrhea-predominant (IBS-D); constipation-predominant
(IBS-C); and alternating bowel habit (IBS-A) according to
the Rome criteria [10].
The primary study endpoint was the relationship be-
tween SIBO and IBS in light of the history of PPI intake.
The secondary study endpoint was the impact of PPI in-
take on the characteristics of SIBO and IBS. Since a total
of 320 patients were needed in a previous study of our
group to disclose a significant relationship between
SIBO and IBS [5] and making the hypothesis that 30 %
of totally enrolled patients will have history of PPI in-
take, to analyse the association between SIBO and IBS
separately among patients without PPI intake and among
patients with PPI intake, it was assumed that a total of
900 patients should be enrolled.
Statistical analysis
In order to explore the primary study endpoint, SIBO was
defined in three different ways using three different cut-
offs of concentrations of colonic type bacteria in the duo-
denal aspirate ie >103, >104 and >105 cfu/ml. Comparisons
of qualitative variables between patients with SIBO and
those without SIBO was done by the Chi-square test.
Odds ratios (ORs) and 95 % confidence intervals (CIs)
were calculated by the Mantel-Haenzel’s statistics. ORs
were compared by the Tarone’s and Breslow-Day’s tests.
Comparisons of quantitative variables were done by the
Student’s “t-test”. In order to define a cut-off value for a
quantitative variable that can discriminate SIBO from
non-SIBO with specificity greater than 90 %, receiver op-
erator curve (ROC) analysis was done. Then forward step-
wise logistic regression analysis was performed taking into
consideration all variables differing between SIBO and
non-SIBO patients at a p value lower than 0.100 and
the intake of PPIs as well. Regarding the secondary
endpoints, patients were divided into those with history
and into those without history of PPI intake. Compari-
sons between these two subgroups comprised the
counts of proximal intestine colonizers where the type
of PPI, the duration of PPI intake and the clinical subtype
of IBS were taken into consideration. 2-sided P values less
than 0.05 were considered significant.
Results
Primary study endpoint
Fully available data were missing in seven patients and
analysis was done in a total of 897 patients (Fig. 1). From
the total analysed patients, 184 (20.5 %) had a history of
recent PPI intake. The overall frequency of SIBO was
17.6 % when the ≥103 cfu/ml diagnostic cut-off was
used; it was 15.6 % when the ≥104 cfu/ml diagnostic cut-
off was used; and it was 10.6 % when the ≥105 cfu/ml
diagnostic cut-off was used. Comparative characteristics
between patients with SIBO and patients without SIBO
are shown in Table 1. Overall, endoscopic findings were
negative for 410 patients. No differences were found be-
tween the two groups of patients regarding history of
PPI intake. However, patients with SIBO were older, they







Age (years, mean ± SD) 63.3 ± 17.0 69.7 ± 17.4 <0.0001
Age ≥60 years (n, %) 475 (64.3) 129 (81.6) <0.0001
BMI (kg/m2, mean ± SD) 26.5 ± 5.3 25.6 ± 5.4 0.071
BMI ≥22 kg/m2 (n, %) 637 (86.5) 128 (81.0) 0.064
Presence of IBS (n, %) 159 (21.5 %) 93 (58.9 %) <0.0001
Type of IBS (n, %)
Predominant-diarrhea 44 (6.0) 33 (20.9) <0.0001
Predominant-constipation 28 (3.5) 8 (5.1) 0.382
Mixed type 87 (11.8) 52 (32.9) <0.0001
Co-morbidities (n, %)
Type 2 diabetes mellitus 171 (23.1) 53 (33.5) 0.008
Chronic heart failure 192 (26.0) 49 (31.0) 0.200
Chronic obstructive
pulmonary disease
74 (10.0) 16 (10.02) 1.000
Chronic renal disease 20 (2.7) 8 (5.1) 0.131
Solid tumor malignancy 67 (9.1) 11 (7.0) 0.441
History of drug intake (n, %)
PPIs 149 (20.2 %) 35 (22.2 %) 0.588
Non-steroidal anti-
inflammatory drugs
30 (4.1 %) 11 (7.0) 0.139
Low-dose aspirin 139 (18.8) 34 (21.5) 0.438
Acenocoumarone 63 (8.5 %) 15 (9.5) 0.644
H2-blockers 15 (2.0) 2 (1.3) 0.751
Antacids 23 (3.1) 8 (5.1) 0.230
Clinical reason for
gastroscopy (n, %)
Dyspepsia 422 (57.1) 94 (59.5) 0.596
Anemia 327 (44.2) 83 (52.5) 0.065
Unknown fever 21 (2.8) 7 (4.4) 0.312
Endoscopic findings (n, %)
Gastritis 388 (52.5) 58 (36.7) <0.0001
Duodenal ulcer 46 (6.2) 12 (7.6) 0.481
Gastric ulcer 9 (1.2) 1 (0.6) 1.000
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had a greater frequency of IBS, of type 2 diabetes melli-
tus (T2DM) and of anemia and a lower frequency of
endoscopic presence of gastritis.
An analysis between presence of SIBO and presence of
IBS was conducted where all diagnostic cut-offs of isola-
tion of bacteria from the duodenal aspirate were consid-
ered ie ≥103 cfu/ml, ≥104 cfu/ml and ≥105 cfu/ml.
Whatever the threshold was, the OR for IBS between pa-
tients with SIBO was greater compared to patients with-
out SIBO. In all cases, the OR for acquisition for IBS in
the setting of SIBO was not greater for patients with a
positive history of PPI intake than patients without PPI
intake (Table 2).
Analysis (Table 3) revealed that age ≥60 years, pres-
ence of IBS and type 2 diabetes mellitus were positively
linked with SIBO. BMI ≥22 kg/m2 and endoscopic gas-
tritis were protective from SIBO. Intake of PPI was not
related with SIBO. To exclude the possibility that gastri-
tis was a confounding factor in analysis, the frequency of
SIBO was analyzed in 451 patients without endoscopic
findings of gastritis; 358 had no history of PPI intake
and 23 had a history of PPI intake; frequency of SIBO
was 21.5 and 24.7 % respectively (p: 0.296).
Secondary endpoints
Analysed patients were divided into those without his-
tory of recent PPI intake (n = 713) and into those with
history of recent PPI intake (n = 184). The absolute
counts of bacteria in the duodenal aspirates did not dif-
fer between groups (Fig. 2a).
Preliminary analysis (data now shown) revealed that
the use of PPIs for ≥9 months prior to endoscopy can be
related with the presence of IBS at specificity greater
than 90 %. As shown in Fig. 2b, no differences in bacter-
ial counts of the duodenal aspirates could be found be-
tween patients with less than or ≥9 month-history of PPI
intake assigned either to the IBS-D subgroup or to the
IBS non-diarrhea subgroup. The same applied for the
type of bacteria isolated from the duodenal aspirates. No
differences were found between patients without and
with history of PPI intake (Table 4). Moreover, the posi-
tive association between SIBO and IBS remained con-
stant irrespective of the type of PPI intake (Table 5).
Discussion
Current findings challenge the concept that intake of
PPIs is favoring the overgrowth of bacteria in the prox-
imal small intestine leading to symptoms compatible
with SIBO like bloating and diarrhea. The rate of PPI in-
take was similar between patients with SIBO and pa-
tients without SIBO as SIBO was determined by small
intestinal aspirate culture. This was also the case with
the absolute number of isolated bacteria whereas intake
of PPIs was also not associated with the likelihood of
SIBO. Instead, the logistic multiple regression analysis
showed that the only factors independently associated
with SIBO were the presence of IBS, T2DM and age
≥60 years. Gastritis and BMI ≥22 kg/m2 were protective
from SIBO.
There is a traditional concept that alteration of gastric
pH, as achieved after long-treatment with PPIs, can
prime bacterial overgrowth and lead to SIBO. Despite
this concept, existing evidence on the association of
SIBO with PPI intake is not-clear cut. Quantitative cul-
ture results of the duodenal aspirates from 675 subjects
who underwent upper GI endoscopy were retrospect-
ively analyzed in relation with the history of PPI intake.
Aspirates were cultured both for aerobe and anaerobe
bacteria and patients were divided into those with nega-
tive aspirates, with intermediate aspirates yielding less
than 105 cfu/ml and with abnormal aspirates yielding
more than 105 cfu/ml. History of PPI intake was
Table 2 Linkage between SIBO and PPI intake
Cut-off of SIBO History of PPI intake SIBO (-) SIBO (+) p OR (95 % CIs) p between ORsa
No Non-IBS 478 (81.0 %) 53 (43.1 %) 0.498
≥103 cfu/ml IBS 112 (19.0 %) 70 (56.9 %) <0.0001 5.63 (3.73–8.51) 0.499
Yes Non-IBS 102 (68.5 %) 12 (34.3 %)
IBS 47 (31.5 %) 23 (65.7 %) <0.0001 4.16 (1.91–9.06)
No Non-IBS 482 (79.9 %) 49 (44.5 %) 0.712
≥104 cfu/ml IBS 121 (20.1 %) 61 (55.5 %) <0.0001 4.95 (3.24–7.59) 0.712
Yes Non-IBS 104 (67.5 %) 10 (33.3 %)
IBS 50 (32.5 %) 20 (66.7 %) 0.001 4.16 (1.81–9.54)
No Non-IBS 497 (77.8 %) 34 (45.9 %) 0.892
≥105 cfu/ml IBS 142 (22.2 %) 40 (54.1 %) <0.0001 4.12 (2.51–6.75) 0.892
Yes Non-IBS 107 (65.6 %) 7 (33.3 %)
IBS 56 (34.3 %) 14 (66.7 %) 0.007 3.82 (1.46–10.01)
aby the Tarone’s and Breslow-Day tests respectively
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positively linked with the presence of intermediate as-
pirates; surprisingly it was not associated with abnor-
mal aspirates [6] showing that many factors other
than intake of PPI prime the development of SIBO.
In another study of 150 participants, a prospective
design was followed. Participants underwent not only
quantitative culture of their duodenal aspirate for the
diagnosis of SIBO but manometry as well to identify
intestinal dysmotility. Dysmotility and PPI intake were
independently associated with a greater frequency of
SIBO. However, the investigators did not provide data
of an interaction between PPI intake and dysmotility
for the generation of SIBO so it cannot be disclosed
whether patients under PPIs were suffering from dys-
motility as well [11].
Prospective treatment of 52 patients with GERD with
esomeprazole for 6 months was associated with the de-
velopment of symptoms compatible with SIBO like
bloating, flatulence and abdominal pain. In these same
symptom-positive patients, SIBO was more frequent by
the glucose breath test. Although findings suggest an as-
sociation between PPI intake for 6 months and develop-
ment of SIBO [12], it should be outlined that the study
did not have a comparator arm. Moreover, patients with
GERD were excluded from our study so that direct com-
parisons cannot be done.
It should be underscored that one main advantage of
the presented analysis is the consideration of time of PPI
treatment that is missing from all former publications.
Fig. 2 Lack of association between bacterial growth in duodenal aspirates and history of PPI intake a Bacterial growth in patients without history
of PPI intake [PPIs(-)] and patients with history of PPI intake [PPIs(+)]; b Bacterial growth in patients with IBS predominant diarrhea [IBS-D(+)] and
the rest of patients [IBS-D(-)] in relation to the time of PPI intake. P values show differences of the indicated comparisons
Table 3 Logistic regression analysis of factors independently
related with SIBO
OR 95 % CIs p
Age ≥60 years 2.36 1.45–3.84 0.001
BMI ≥22 kg/m2 0.60 0.36–0.99 0.049
Presence of IBS 6.28 4.26–9.25 <0.0001
Type 2 diabetes mellitus 1.59 1.04–2.45 0.032
Intake of PPIs 0.76 0.45–1.42 0.765
Anemia 1.24 0.84–1.84 0.271
Endoscopic gastritis 0.47 0.32–0.69 <0.0001
Abbreviations: CI confidence interval, OR odds ratio
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Three main limitations of the study should be reported.
The first is the lack of culture for anaerobes. The second
is the small subgroups of patients with SIBO and IBS
despite the large number of performed endoscopies. The
third is the lack of use of a method for prevention of
contamination during endoscopy. However, the aerobic
bacteria isolated from the duodenum were mainly
species usually inhabiting the large bowel. This makes
the chance for contamination unlikely.
The lack of association between intake of PPIs and
SIBO reinforces the recently developed therapeutic con-
cept for SIBO eradication as a means for management of
IBS. Although our study failed to identify an association
between PPI intake and SIBO, it clearly showed a posi-
tive association between SIBO and IBS particularly with
the IBS-D subtype. Although factors like T2DM, age
above 60 years, gastritis and BMI above 22 kg/m2 may
modulate SIBO, the association between SIBO and IBS
is independent from these factors. As a consequence,
eradication of SIBO may be part of the algorithm for the
management of IBS. A recent meta-analysis has con-
firmed treatment benefit in IBS with antibiotic treat-
ment; this is pronounced with the non-absorbable
rifaximin antibiotic [13]. Results of the big TARGET1
and TARGET2 randomized clinical trials were not in-
cluded in this meta-analysis. In these two trials, oral
rifaximin 550 mg tid for ten days improved considerably
signs of IBS compared with placebo when given in pa-
tients with IBS without constipation (40.8 % versus
31.2 %, p = 0.01 in TARGET 1 trial; and 40.6 % versus





p OR (95 % CIs)
None IBS (-) 478 (80.9) 53 (43.4) <0.0001 5.50 (3.64–8.32)
IBS (+) 113 (19.1) 69 (56.6)
Omeprazole IBS (-) 38 (82.6) 1 (12.5) <0.0001 33.25 (3.57–309.2)
IBS (+) 8 (17.4) 7 (87.5)
Esomeprazole IBS (-) 37 (56.1) 11 (40.7) 0.043 1.82 (1.02–4.60)
IBS (+) 29 (43.9) 16 (59.3)
Pantoprazole IBS (-) 9 (81.8) 0 (0) a a
IBS (+) 2 (18.2) 1 (100)
Abbreviations: CI confidence interval, OR odds ratio
acannot be calculated because one value is zero
Table 4 Impact of PPI intake on the type of bacteria of the duodenal aspirates in relation to the presence of IBS or not
Type of bacteria No PPI intake (%) PPI intake (%) p
SIBO without IBS (n = 65) Escherichia coli 11 (20.7) 2 (16.7)
Klebsiella pneumoniae 11 (20.7) 2 (16.7)
Enterobacter cloacae 7 (13.2) 0 (0)
Staphylococcus aureus 6 (11.3) 2 (16.7)
Enterococcus faecalis 3 (5.7) 1 (8.3)
Pseudomonas aeruginosa 3 (5.7) 0 (0)
Enterobacter aerogenes 2 (3.8) 3 (25.0) 0.644
Proteus mirabilis 1 (1.9) 0 (0)
Serratia marscecens 2 (3.8) 0 (0)
Acinetobacter baumannii 2 (3.8) 0 (0)
Stenotrophomonas maltophilia 1 (1.9) 0 (0)
Citrobacter freundii 0 (0) 1 (8.3)
SIBO with IBS (n = 93) Escherichia coli 22 (31.4) 6 (26.1)
Enterobacter cloacae 9 (12.9) 0 (0)
Klebsiella pneumoniae 8 (11.4) 6 (26.1)
Enterococcus faecium 4 (5.7) 0 (0)
Staphylococcus aureus 3 (4.3) 1 (4.3) 0.125
Enterococcus faecalis 3 (4.3) 2 (8.7)
Enterobacter aerogenes 3 (4.3) 2 (8.7)
Klebsiella oxytoca 3 (4.3) 1 (4.3)
Pseudomonas aeruginosa 3 (4.3) 0 (0)
Acinetobacter baumannii 2 (2.9) 0 (0)
Serratia marscecens 1 (1.4) 2 (8.7)
P values indicate differences in the distribution of bacterial species between patients wihout and with history of PPI intake
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32.2 %, p = 0.03 in TARGET 2 trial) [14]. The in vitro ac-
tivity of rifaximin was studied against the bacteria iso-
lated from 117 of the patients included in our
prospective cohort. To study the over-time killing effect
of rifaximin, bile salts were added in the growth medium
to simulate the intestinal environment. Pronounced
time-kill effect was found at a concentration of 500 μg/ml
against isolates of Escherichia coli, Klebsiella pneumoniae
and Enterococcus faecalis that caused SIBO in our patients
[15]. This concentration is considerably lower than the
concentration of the drug found in the stool [16].
Conclusions
Analysis of a cohort of 897patients with prospective
quantitative culture of the duodenal aspirates did not
find any association between SIBO and intake of PPI.
Instead the association between IBS and SIBO was com-
pletely independent from PPI intake. Although gastritis
was protective against SIBO, results show that PPI in-
take cannot prime SIBO.
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